Get Started

ALGS

NASD Aligos Therapeutics, Inc.
Oct 30, 2026 · 8:44 PM ET LAST TRADE Market Closed

$4.80 ↑ +0.00 (+0.00%) Trading Up from the previous close of $4.80, $0.25 below the day’s high of $5.05

YTD change
-48.50%
vs 20-day SMA
-6.64%
vs 200-day SMA
-23.33%

Price ranges

Previous day
$5.02 $5.38
open $5.07 close $5.03
-$0.04 (-0.79%)
Today
$4.75 $5.05
open $4.99 now $4.80
-$0.19 (-3.81%)
Past week
$4.55 $5.38
from $4.82 now $4.80
-$0.02 (-0.41%)
Past month
$4.55 $5.72
from $5.50 now $4.80
-$0.70 (-12.73%)
This year
$3.98 $10.49
from $9.32 now $4.80
-$4.52 (-48.50%)

Price & Performance

-1.19 (-19.87%) / 6M

$3.79$5.17$6.56$7.94Apr 30Jul 31Oct 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 99.5% away from all-time highs of $937.75
  • ALGS is down 48% since the beginning of the year
  • ALGS is down 41% over the past 12 months
  • ALGS is down 13% over the past 1 month
  • 13% of all ALGS investors are betting against ALGS

ALGS reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -41.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.14
Earnings momentum +93.9% Quarterly EPS growth
Quarterly change +93.9%

Valuation

P/E ratio N/A
Enterprise value $25.5M
Beta 2.58

Balance sheet & scale

IncomeN/A
Revenue$31.5M
Cash$30.4M
Debt$3.5K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $30.0M

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.